DDInter1725 DDInter434
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf
Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bacitracin
Bacitracin {u} (Compound) resembles {v} (Compound) Colistimethate
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Polymyxin B
Polymyxin B {u} (Compound) resembles {v} (Compound) Colistimethate
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bacitracin
Bacitracin {u} (Compound) resembles {v} (Compound) Colistin
Colistin {u} (Compound) resembles {v} (Compound) Colistimethate
Sulfasalazine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Bacitracin
Bacitracin {u} (Compound) resembles {v} (Compound) Colistimethate
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Polymyxin B
Polymyxin B {u} (Compound) resembles {v} (Compound) Bacitracin
Bacitracin {u} (Compound) resembles {v} (Compound) Colistimethate
Sulfasalazine {u} (Compound) downregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Bacitracin
Bacitracin {u} (Compound) resembles {v} (Compound) Colistimethate
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Polymyxin B
Polymyxin B {u} (Compound) resembles {v} (Compound) Colistin
Colistin {u} (Compound) resembles {v} (Compound) Colistimethate
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bacitracin
Bacitracin {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Colistimethate
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bacitracin
Bacitracin {u} (Compound) resembles {v} (Compound) Colistimethate
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Polymyxin B
Polymyxin B {u} (Compound) is included by {v} (Pharmacologic Class) Polymyxins
Polymyxins {u} (Pharmacologic Class) includes {v} (Compound) Colistimethate
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Colistimethate (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B and Polymyxin B (Compound) resembles Colistimethate (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Colistin (Compound) and Colistin (Compound) resembles Colistimethate (Compound)
Sulfasalazine (Compound) binds PTGS2 (Gene) and Sulfasalazine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Bacitracin (Compound) and Bacitracin (Compound) resembles Colistimethate (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B and Polymyxin B (Compound) resembles Bacitracin (Compound) and Bacitracin (Compound) resembles Colistimethate (Compound)
Sulfasalazine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Bacitracin (Compound) and Bacitracin (Compound) resembles Colistimethate (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B and Polymyxin B (Compound) resembles Colistin (Compound) and Colistin (Compound) resembles Colistimethate (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Colistimethate (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Colistimethate (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B and Polymyxin B (Compound) is included by Polymyxins (Pharmacologic Class) and Polymyxins (Pharmacologic Class) includes Colistimethate (Compound)